Actualités

Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.

Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad

Jazz Pharmaceuticals (NASDAQ:JAZZ) and AbCellera (NASDAQ:ABCL) have signed a preclinical collaboration, option and licensing agreement focused on the discovery and development of T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. The partnership combines AbCellera’s antibody discovery capabilities with Jazz’s oncology development expertise as the companies seek to advance new cancer therapies.

The average of price targets set by Wall Street analysts indicates a potential upside of 85.6% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AbCellera Biologics (ABCL) has been drawing fresh attention after positive interim Phase 1 data for lead antibody ABCL635 and stronger than expected Q1 revenue growth, as the company continues to expand its focus on proprietary drug development. See our latest analysis for AbCellera Biologics. The recent pullback, with a 1 day share price return down 11.8% to US$5.62 and a 7 day share price return down 8.9%, comes after a strong 90 day share price return of 59.7% and a 1 year total...

AbCellera Biologics (NasdaqGS:ABCL) reported positive Phase 1 results for its lead antibody, ABCL635, targeting menopause-related hot flashes. The company is shifting its model from partner-based antibody discovery toward developing its own proprietary drugs. AbCellera appointed Dr. Victor Sandor, a clinical development leader with experience in multiple regulatory drug approvals, to its Board of Directors. AbCellera has built its business around antibody discovery partnerships, and the...

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech’s pipeline and lead clinical program. Booth said

Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

AbCellera Biologics Inc. recently reported past first-quarter 2026 results, with revenue rising to US$8.32 million from US$4.24 million a year earlier, while net loss narrowed slightly to US$43.17 million and the company highlighted interim Phase 1 data for its ABCL635 antibody candidate. The combination of higher revenue, a modest improvement in per-share losses, and early ABCL635 safety and pharmacokinetic data moving the program toward Phase 2 has drawn fresh attention to how AbCellera’s...

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 12, 2026, Stifel raised the firm’s price target on AbCellera Biologics Inc. (NASDAQ:ABCL) to $8 from $7 and kept a Buy rating on the shares. The firm said preliminary safety, pharmacokinetic, and pharmacodynamic data from the […]

The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful ... 7 Healthcare AI Stocks Under $50 With Huge Upside Potential

Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.

AbCellera Biologics Inc. ( NASDAQ:ABCL ) defied analyst predictions to release its quarterly results, which were ahead...

AbCellera Biologics (NasdaqGS:ABCL) reported positive interim Phase 1 results for its lead asset ABCL635 in treating moderate to severe vasomotor symptoms associated with menopause. The data showed strong target engagement, a favorable safety profile, and support for once monthly dosing. Based on these results, AbCellera is moving ABCL635 into Phase 2 trials, with efficacy data expected in Q3 2026. For investors watching AbCellera Biologics at a share price of $4.95, the move of ABCL635...

AbCellera Biologics Inc (ABCL) progresses its lead program into Phase II, despite reporting a net loss and increased R&D expenses.

AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years. President and CEO Dr. Carl

Tryn Stimart: Thank you for joining us for AbCellera Biologics Inc.'s First Quarter 2026 Earnings Call. Doctor Carl L. Hansen, AbCellera Biologics Inc.'s President and CEO, Doctor Sarah Noonberg, AbCellera Biologics Inc.'s Chief Medical Officer, and Andrew Booth, AbCellera Biologics Inc.'s Chief Financial Officer, are speaking on today's call.

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +36.36% and +68.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ABSCI CORP (ABSI) delivered earnings and revenue surprises of +5.00% and -90.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

In recent days, attention has centred on AbCellera Biologics ahead of its upcoming Q1 earnings call and the May 11, 2026 Phase 1 interim data update for ABCL635, a clinical candidate targeting menopause-related vasomotor symptoms. Investor optimism has been reinforced by analyst commentary on the potential competitiveness of ABCL635, growing insider and institutional interest, and AbCellera’s progress in advancing 19 molecules into clinical development across internal and partnered...